CSIMarket
 
Ptc Therapeutics inc   (NASDAQ: PTCT)
Other Ticker:  
 
 
Price: $49.9900 $0.61 1.235%
Day's High: $50.62 Week Perf: 8.32 %
Day's Low: $ 49.20 30 Day Perf: 7.41 %
Volume (M): 912 52 Wk High: $ 51.74
Volume (M$): $ 45,571 52 Wk Avg: $35.84
Open: $49.51 52 Wk Low: $23.58



 Market Capitalization (Millions $) 3,824
 Shares Outstanding (Millions) 77
 Employees 995
 Revenues (TTM) (Millions $) 928
 Net Income (TTM) (Millions $) -579
 Cash Flow (TTM) (Millions $) 331
 Capital Exp. (TTM) (Millions $) 141

Ptc Therapeutics Inc
Ptc Therapeutics Inc is a publicly traded biopharmaceutical company headquartered in South Plainfield, New Jersey, USA. The company has a focus on the discovery, development, and commercialization of innovative medicines to treat rare diseases. Ptc Therapeutics Inc is a pioneer in the field of RNA biology, with a particular emphasis on identifying small molecules that can modulate RNA activity.

The company is best known for its groundbreaking work in developing Ataluren or Translarna, an oral medication, for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation. The drug has also been approved by the European Commission and is marketed under the name Translarna. The company also has several other pipeline products under development, targeting various rare genetic disorders.

The company was founded in 1998 as PTC Therapeutics, Inc. by Stuart W. Peltz, Ph.D., and he acted as the CEO of the company from its inception. The company went public in 2013 and is now traded on the NASDAQ Stock Exchange (PTCT).

Ptc Therapeutics has grown rapidly over the years through strategic acquisitions and collaborations. The company's strategic partners include Roche, Biogen IDEC, Genzyme, and AstraZeneca. Ptc Therapeutics is also involved in various collaborations with academic institutions and government agencies to advance research in RNA biology and therapy.

Ptc Therapeutics actively participates in philanthropic efforts, including partnering with organizations such as Parent Project Muscular Dystrophy, a non-profit organization aimed at finding a cure for Duchenne muscular dystrophy.

In conclusion, Ptc Therapeutics Inc is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for rare genetic disorders. The company's innovative work in RNA biology has led to the development of groundbreaking therapeutics for DMD and several other rare diseases. The company continues to pursue its goal of advancing research and development in RNA therapeutics, collaborating with academic institutions, government agencies, and non-profit organizations to find cures for rare genetic diseases.


   Company Address: 500 Warren Corporate Center Drive Warren 7059 NJ
   Company Phone Number: 222-7000   Stock Exchange / Ticker: NASDAQ PTCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        5.24% 
BMY   -2.64%    
REGN        4.92% 
TEVA   -3.53%    
VRTX        5.21% 
VTRS   -3.15%    
• View Complete Report
   



Ptc Therapeutics Inc

PTC Therapeutics Inc. Bounces Back: Redemption of Losses in First Quarter Earnings Report

The stock market is rife with money-making opportunities, and investors are constantly on the lookout for promising companies to invest in. PTC Therapeutics Inc., a major player in the pharmaceutical industry, is one such company that has caught the attention of many discerning investors. Despite facing a decrease in revenue and an overall challenging first quarter of 2024, PTC Therapeutics Inc. has managed to trim its diminishing returns, displaying resilience and determination.
In the first quarter of the 2024 earnings season, PTC Therapeutics Inc. reported a decline in revenue by -4.657% to $210.12 million. This may seem like a setback, but it is vital to put it into perspective. When comparing it with the previous financial reporting period, where revenue tumbled by an alarming -31.57% from $307.06 million, PTC Therapeutics Inc. has shown signs of improvement. Despite the challenging market conditions, the company has successfully mitigated further decline in revenue.

Ptc Therapeutics Inc

How Ptc Therapeutics Inc is Overcoming Losses with a Remarkable Revenue Surge

Ptc Therapeutics Inc, a leading biopharmaceutical company, recently released its financial results for the October to December 31, 2023 fiscal period. Despite reporting a net loss of $-1.97 per share, the company showed improvement compared to the same period last year when the loss per share was $-2.32. Notably, this also marks an increase from the previous reporting period's loss per share of $-1.76.
On a positive note, Ptc Therapeutics Inc witnessed a significant rise in revenue during this fiscal period, with a strong growth of 83.412%. The company generated $307.06 million in revenue, compared to $167.41 million in the same period a year ago. Additionally, the sequential revenue surged by 56.202% from $196.58 million.

Ptc Therapeutics Inc

Ptc Therapeutics Inc. Grapples with Impending Crisis Amidst Decreased Orders in Q3 2023

/>Ptc Therapeutics Inc., a leading biopharmaceutical company, experienced a challenging July to September 2023 period, overwhelmed by lower demand and dwindling revenue. Despite recent gains in share price, the company's financials raise concerns as it reported a larger shortfall and decreased revenue year on year. This article will analyze the financial results to delve deeper into the factors contributing to Ptc Therapeutics Inc.'s struggling performance.
Dwindling Revenue and Extended Deficit:
During the July to September 2023 period, Ptc Therapeutics Inc. faced a significant decline in revenue, marking a year-on-year decrease of 9.465%. Revenue stood at $196.58 million, compared to $213.81 million in the prior quarter. This downward trend in revenue culminated in a net shortfall of $-132.970 million, a substantial increase from $-109.315 million reported a year ago.

Ptc Therapeutics Inc

Ptc Therapeutics Inc Reports Unexpected Jump in Q2 2023 Revenue, Encountering a Paradoxical Slump

Financial news report:

Ptc Therapeutics Inc, a biopharmaceutical company, has reported a significant surge in revenue for the April to June 30, 2023 period. The company's revenue increased by 29.169% to $213.81 million compared to the corresponding reporting period a year prior. However, it also reported an increased deficit per share at $-2.66 per share, compared to $-1.88 per share in the previous year.
Interestingly, despite the increase in revenue, there was a slight decrease in revenue by -2.983% from $220.38 million. Additionally, Ptc Therapeutics Inc recorded a net deficit of $-198.883 million for the most recent fiscal period, which was larger than the $-152.087 million deficit from the previous year.







Ptc Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com